LoginRegister
    Roche begins Phase III clinical trial of Actemra in hospitalised patients with severe COVID-19 pneumoniaRoche begins Phase III clinical trial of Actemra in hospitalised patients with severe COVID-19...
    NPPA, regularly monitoring situations of prices and availability of essentials medicines, says MinisterNPPA, regularly monitoring situations of prices and availability of essentials medicines, says...
    CDSCO lays down the Timeline for testing of various classes of New drugsCDSCO lays down the Timeline for testing of various classes of New drugs
    Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia AreataLilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata
    Cipla joins hands with CSIR-IICT to develop coronavirus drugCipla joins hands with CSIR-IICT to develop coronavirus drug
    Pfizer, Biontech join hands to co-develop mRNA-based coronavirus vaccinePfizer, Biontech join hands to co-develop mRNA-based coronavirus vaccine
    Emami share buyback size likely to be Rs 900-1000 croreEmami share buyback size likely to be Rs 900-1000 crore
    NPPA orders Surgical, Protective Masks makers, importers to provide dataNPPA orders Surgical, Protective Masks makers, importers to provide data
    Price fixation of drugs saves Rs 12,447 crores per annum, says NPPA dataPrice fixation of drugs saves Rs 12,447 crores per annum, says NPPA data
    Regeneron, Sanofi begin testing use of Arthritis Drug Kevzara to treat COVID-19Regeneron, Sanofi begin testing use of Arthritis Drug Kevzara to treat COVID-19
    Alembic Pharma gets USFDA EIR for API Facility at KarakhadiAlembic Pharma gets USFDA EIR for API Facility at Karakhadi
    Dr Reddys Labs launches Ziprasidone Mesylate for Injection in US MarketDr Reddy's Labs launches Ziprasidone Mesylate for Injection in US Market
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X